Kim Steegen to Humans
This is a "connection" page, showing publications Kim Steegen has written about Humans.
Connection Strength
0,809
-
Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS. 2023 05 01; 37(6):1009-1011.
Score: 0,064
-
Compelling evidence for unconditional shift to dolutegravir. Lancet HIV. 2022 08; 9(8):e523-e524.
Score: 0,062
-
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment. Pediatr Infect Dis J. 2022 10 01; 41(10):827-834.
Score: 0,062
-
Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021 09 15; 76(10):2659-2665.
Score: 0,058
-
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa. J Int AIDS Soc. 2021 05; 24(5):e25706.
Score: 0,057
-
Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
Score: 0,042
-
Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa. J Infect Dis. 2016 Dec 15; 214(12):1826-1830.
Score: 0,041
-
HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
Score: 0,041
-
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. PLoS One. 2014; 9(5):e97067.
Score: 0,035
-
Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J Virol Methods. 2007 Dec; 146(1-2):178-87.
Score: 0,022
-
Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J Clin Microbiol. 2007 Oct; 45(10):3342-51.
Score: 0,022
-
A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods. 2006 May; 133(2):137-45.
Score: 0,020
-
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses. 2024 12 06; 16(12).
Score: 0,018
-
K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine. Viruses. 2024 Sep 20; 16(9).
Score: 0,018
-
Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi's National HIV Treatment Program. Viruses. 2023 12 23; 16(1).
Score: 0,017
-
Recommendations on data sharing in HIV drug resistance research. PLoS Med. 2023 Sep; 20(9):e1004293.
Score: 0,017
-
Resistance is common in paediatric patients failing ART in South Africa. J Antimicrob Chemother. 2023 05 03; 78(5):1160-1167.
Score: 0,016
-
Guidance for SARS-CoV-2 RNA-Based Molecular Assay Analytical Performance Evaluations. Methods Mol Biol. 2022; 2511:99-115.
Score: 0,015
-
Preparing for the next pandemic: Lessons from rapid scale-up of SARS-CoV-2 testing in a South African high-throughput automated HIV molecular laboratory. Int J Infect Dis. 2021 Sep; 110:1-3.
Score: 0,014
-
High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Medicine (Baltimore). 2020 Sep 11; 99(37):e21661.
Score: 0,014
-
Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second-line ART. J Int AIDS Soc. 2020 06; 23(6):e25501.
Score: 0,013
-
PhyloPi: An affordable, purpose built phylogenetic pipeline for the HIV drug resistance testing facility. PLoS One. 2019; 14(3):e0213241.
Score: 0,012
-
Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes. J Acquir Immune Defic Syndr. 2019 01 01; 80(1):73-78.
Score: 0,012
-
Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV. 2018 11; 5(11):e638-e646.
Score: 0,012
-
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine. 2017 Apr; 18:225-235.
Score: 0,011
-
Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Health. 2016 09; 21(9):1131-7.
Score: 0,010
-
Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J Antimicrob Chemother. 2016 10; 71(10):2918-27.
Score: 0,010
-
High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One. 2015; 10(2):e0118145.
Score: 0,009
-
Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe. Biomed Res Int. 2014; 2014:102598.
Score: 0,009
-
Integration of clinical point-of-care requirements in a DNA microarray genotyping test. Biosens Bioelectron. 2014 Nov 15; 61:605-11.
Score: 0,009
-
Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa. AIDS Res Hum Retroviruses. 2014 Mar; 30(3):289-93.
Score: 0,008
-
Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol. J Virol Methods. 2013 Dec; 194(1-2):300-7.
Score: 0,008
-
A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only. J Clin Microbiol. 2013 Jun; 51(6):1757-61.
Score: 0,008
-
HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. PLoS One. 2012; 7(4):e34708.
Score: 0,008
-
Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J Virol Methods. 2010 Feb; 163(2):253-7.
Score: 0,006
-
Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother. 2009 May; 53(5):2185-8.
Score: 0,006
-
Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes. J Virol Methods. 2005 Sep; 128(1-2):47-53.
Score: 0,005